Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma

June 11, 2015
Catherine M. Diefenbach, MD

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).